⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BBIO News
BridgeBio Pharma, Inc. Common Stock
Muscular Dystrophy Association Announces Łukasz Sznajder, PhD, MSc, to Receive Inaugural MDA Research Momentum Award
globenewswire.com
ARX
BIIB
BBIO
NVS
RGNX
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
globenewswire.com
BBIO
Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals
globenewswire.com
NVS
GILD
BMY
REGN
CRSP
NTLA
EDIT
BBIO
AZN
SGMO
BirchBioMed reçoit l'approbation de Santé Canada pour sa crème topique (NPN 80147114) USA - Français USA - Deutsch USA - English USA - English
prnewswire.com
BBIO
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
BBIO
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Year-End 2025 SPAC Market Update & Outlook
businesswire.com
BBIO
Skeletal Dysplasia Market Analysis Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031
globenewswire.com
TYRA
BBIO
BMN
BE
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
globenewswire.com
BBIO
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
globenewswire.com
BBIO